Evidence map›Paper›PMID 37457712›Full record

ArticleFrontiers in immunology2023

Downregulation of monocyte miRNAs: implications for immune dysfunction and disease severity in drug-resistant tuberculosis.

Pavithra Sampath, Manju Moorthy, Athul Menon, Lekshmi Madhav, Aishwarya Janaki, Madhavan Dhanapal, Alangudi Palaniappan Natarajan, Syed Hissar, Uma Devi Ranganathan, Gopalakrishna Ramaswamy and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Epigenetic Mechanisms Induced byInternational journal of molecular sciences · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Pavithra SampathDepartment of Immunology, Indian Council of Medical Research (ICMR)-National Institute for Research in Tuberculosis (NIRT), Chennai, India.
Manju MoorthyTheraCUES Innovations Pvt. Ltd, Bangalore, India.
Athul MenonTheraCUES Innovations Pvt. Ltd, Bangalore, India.
Lekshmi MadhavTheraCUES Innovations Pvt. Ltd, Bangalore, India.
Aishwarya JanakiDepartment of Immunology, Indian Council of Medical Research (ICMR)-National Institute for Research in Tuberculosis (NIRT), Chennai, India.
Madhavan DhanapalDepartment of Immunology, Indian Council of Medical Research (ICMR)-National Institute for Research in Tuberculosis (NIRT), Chennai, India.
Alangudi Palaniappan NatarajanDepartment of Clinical Research, ICMR-National Institute of Research in Tuberculosis (NIRT), Chennai, India.
Syed HissarDepartment of Clinical Research, ICMR-National Institute of Research in Tuberculosis (NIRT), Chennai, India.
Uma Devi RanganathanDepartment of Immunology, Indian Council of Medical Research (ICMR)-National Institute for Research in Tuberculosis (NIRT), Chennai, India.
Gopalakrishna RamaswamyTheraCUES Innovations Pvt. Ltd, Bangalore, India.
Ramalingam BethunaickanDepartment of Immunology, Indian Council of Medical Research (ICMR)-National Institute for Research in Tuberculosis (NIRT), Chennai, India.
Indian Council of Medical Research · INNational Institute of Research in Tuberculosis · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Monocyte miRNAs govern both protective and pathological responses during tuberculosis (TB) through their differential expression and emerged as potent targets for biomarker discovery and host-directed therapeutics. Thus, this study examined the miRNA profile of sorted monocytes across the TB disease spectrum [drug-resistant TB (DR-TB), drug-sensitive TB (DS-TB), and latent TB] and in healthy individuals (HC) to understand the underlying pathophysiology and their regulatory mechanism. Methods: We sorted total monocytes including three subsets (HLA-DR Results: The outcome was the differential expression of 107 miRNAs particularly the downregulation of miRNAs in the active TB groups (both drug-resistant and drug-sensitive). The miRNA profile revealed differential expression signatures: i) decline of miR-548m in DR-TB alone, ii) decline of miR-486-3p in active TB but significant elevation only in LTB iii) elevation of miR-132-3p only in active TB (DR-TB and DS-TB) and iv) elevation of miR-150-5p in DR-TB alone. The directionality of functions mediated by monocyte miRNAs from Gene Set Enrichment Analysis (GSEA) facilitated two phenomenal findings: i) a bidirectional response between active disease (activation profile in DR-TB and DS-TB compared to LTB and HC) and latent infection (suppression profile in LTB vs HC) and ii) hyper immune activation in the DR-TB group compared to DS-TB. Conclusion: Thus, monocyte miRNA signatures provide pathological clues for altered monocyte function, drug resistance, and disease severity. Further studies on monocyte miRNAs may shed light on the immune regulatory mechanism for tuberculosis.

Indexed as

MicroRNAsTuberculosisTuberculosis, Multidrug-ResistantDown-RegulationHLA-DR AntigensHumansLeukocytes, MononuclearMonocytesPatient AcuityHLA-DR AntigensMicroRNAsdrug-resistant -TBimmune dysfunctionmonocyte miRNAmonocyte sortingMycobacterium tuberculosisNanoString

Identifiers

PMID37457712
PMCPMC10345223
OpenAlexW4382786570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.